Intellia Therapeutics Inc (NTLA) — Cash Flow-to-Debt Ratio
Intellia Therapeutics Inc (NTLA) has a Cash Flow-to-Debt Ratio of -0.41x as of December 2025, meaning its operating cash flow of $-69.28 Million could theoretically repay 0% of its total liabilities ($170.73 Million) in one year. Explore NTLA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Intellia Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Intellia Therapeutics Inc across 12 annual periods. Also explore Intellia Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Intellia Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Intellia Therapeutics Inc. For market capitalisation and broader financial context, see Intellia Therapeutics Inc (NTLA) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.04x | $-348.88 Million | $170.73 Million | ▼ -86.9% |
| 2024 | -1.09x | $-348.88 Million | $319.06 Million | ▲ +30.4% |
| 2023 | -1.57x | $-394.09 Million | $250.81 Million | ▼ -34.1% |
| 2022 | -1.17x | $-333.29 Million | $284.53 Million | ▼ -32.3% |
| 2021 | -0.89x | $-225.03 Million | $254.22 Million | ▼ -164.7% |
| 2020 | -0.33x | $-49.91 Million | $149.25 Million | ▲ +79.1% |
| 2019 | -1.60x | $-103.24 Million | $64.40 Million | ▼ -81.6% |
| 2018 | -0.88x | $-61.26 Million | $69.39 Million | ▼ -2.3% |
| 2017 | -0.86x | $-65.28 Million | $75.64 Million | ▼ -313.0% |
| 2016 | 0.41x | $36.11 Million | $89.13 Million | ▲ +439.7% |
| 2015 | -0.12x | $-1.76 Million | $14.78 Million | ▲ +89.3% |
| 2014 | -1.11x | $-3.48 Million | $3.13 Million | — |